TERT and central nervous system cancer: In gliomas, the overall survival (OS) (10.9 vs. 15.9) and progression-free survival (PFS) (6.9 vs. 12.3) of the TERT promoter mutant group were significantly lower than those of the TERT promoter wild-type group, representing a poorer prognosis [236].